Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin in Raynaud Phenomenon
NCT05125029Phase 4Completed
- Sponsor
- Emory University
- Start
- Feb 2022
- Primary completion
- May 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of neuronox in Raynaud phenomenon, sponsored by Emory University. Started Feb 2022; status: completed.
02
Drugs
neuronox
03
Conditions
Raynaud phenomenon
Beyond the preview
Go deeper on NCT05125029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05125029.